Follicular Lymphoma
Conference Coverage
Reduced-intensity conditioning may not preserve fertility in young girls after bone marrow transplant
ORLANDO – Talking with a child who is about to undertake chemo about preserving her fertility may be the furthest thing from everyone’s mind, but...
Article
MAGNIFY in relapsed/refractory mantle cell lymphoma
MAGNIFY is actively recruiting patients.
Conference Coverage
Inhibitor produces durable responses in rel/ref iNHL
WASHINGTON, DC—An investigational drug can produce durable responses and has a manageable safety profile in patients with relapsed or refractory...
Conference Coverage
Half of patients retain response to CAR T-cell therapy
WASHINGTON, DC—Roughly half of patients who responded to chimeric antigen receptor (CAR) T-cell therapy in the ZUMA-1 trial have retained that...
Article
Demystifying the diagnosis and classification of lymphoma: a guide to the hematopathologist’s galaxy
News
Phase 2 study of daratumumab in NHL won’t proceed
The phase 2 CARINA study of daratumumab in non-Hodgkin lymphoma (NHL) will not proceed to stage 2, according to Genmab A/S and Janssen Biotech,...
News
Therapy can produce durable CRs in NHL
When given after low-dose chemotherapy, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy can produce durable complete responses (CRs)...
Conference Coverage
Pathogenesis of breast-implant-associated ALCL
SAN FRANCISCO—A small study suggests an abnormal immune response characterized by the production of interleukin-13 (IL-13) underlies the...
Conference Coverage
CAR designers report high B-cell cancer response rates
A CAR-T cell construct consisting of autologous CD4-positive and CD-8 positive T cells delivered in a single infusion was associated with high...
Conference Coverage
Adding rituximab to reduced intensity conditioning boosts PFS
ORLANDO – Rituximab conferred a significant progression-free survival benefit in reduced intensity conditioning regimens for patients with B-cell...